Contineum Therapeutics (CTNM) Operating Leases (2023 - 2026)

Contineum Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Operating Leases rose 52.94% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $7.0 million (up 52.94% YoY), while the FY2025 annual figure was $8.2 million, up 71.62% from the prior year.
• Operating Leases was $7.0 million for Q1 2026 at Contineum Therapeutics, down from $8.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $8.2 million in Q4 2025 to a low of $108000.0 in Q4 2023.
• Historically, Operating Leases has averaged $3.7 million across 4 years, with a median of $4.3 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Operating Leases jumped 4350.93% in 2024, then soared 52.94% in 2026.
• A 4-year view of Operating Leases shows it stood at $108000.0 in 2023, then surged by 4350.93% to $4.8 million in 2024, then soared by 71.62% to $8.2 million in 2025, then fell by 15.71% to $7.0 million in 2026.
• The last three Operating Leases figures came in at $7.0 million (Q1 2026), $8.2 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.